MedTrace Logo

The Psychophysiological Effect of Simulated and Terrestrial Altitude

NCT04075565 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-19

Study results available
· View outcomes & findings →

Summary

The aim of this study is to compare the psychophysiological effects of terrestrial altitude with a normobaric, hypoxic situation.

Conditions

  • Hypoxia
  • Altitude Hypoxia
  • Altitude Sickness
  • Altitude
  • Mountain Sickness
  • Hypoxia, Altitude

Interventions

BEHAVIORAL

Terrestrial altitude

Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.

BEHAVIORAL

Cloud 9

Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application. Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined.

Sponsors & Collaborators

  • University of Portsmouth

    collaborator OTHER

  • Vrije Universiteit Brussel

    collaborator OTHER

  • University of Applied Sciences and Arts of Southern Switzerland

    lead OTHER

Principal Investigators

  • Ron Clijsen, PhD · University of Applied Sciences and Arts of Southern Switzerland (SUPSI)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2021-03-31
Completion
2022-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075565 on ClinicalTrials.gov